A cross-sectional survey of cancer patients seen at the Seattle Cancer Care Alliance was conducted over a 6-week period between 2015 and 2016. In Washington State, Cannabis was legalized for medicinal use in 1998 and for recreational use in 2012. Of the 2,737 possible participants, 936 (34%) completed the anonymous questionnaire. Twenty-four percent of patients considered themselves active Cannabis users. Similar numbers of patients inhaled (70%) or used edibles (70%), with dual use (40%) being common. Non–mutually exclusive reasons for Cannabis use were physical symptoms (75%), neuropsychiatric symptoms (63%), recreational use/enjoyment (35%), and treatment of cancer (26%). The physical symptoms most commonly cited were pain, nausea, and loss of appetite. The majority of patients (74%) stated that they would prefer to obtain information about Cannabis from their cancer team, but less than 15% reported receiving information from their cancer physician or nurse.
A population-based case-control study of 611 lung cancer patients revealed that chronic low Cannabis exposure was not associated with an increased risk of lung cancer or other upper aerodigestive tract cancers and found no positive associations with any cancer type (oral, pharyngeal, laryngeal, lung, or esophagus) when adjusting for several confounders, including cigarette smoking.
Australia's National Cannabis Prevention and Information Centre (NCPIC) states that the buds (flowers) of the female cannabis plant contain the highest concentration of THC, followed by the leaves. The stalks and seeds have "much lower THC levels". The UN states that leaves can contain ten times less THC than the buds, and the stalks one hundred times less THC.
If you decide to cut back or stop after using cannabis regularly, you may experience psychological and physical withdrawal symptoms such as irritability, sleep difficulty, vivid dreams, and decreased appetite. Talk to a trusted friend or family member about your plan to change, and ask them to look out for and support you. Alternatively, call Alcohol and Drug Helpline 0800 787 797 for confidential, non-judgmental advice and referral to a local service provider.
There is great variation in Cannabis sativa, because of disruptive domestication for fiber, oilseed, and narcotic resin, and there are features that tend to distinguish these three cultigens (cultivated phases) from each other. Moreover, density of cultivation is used to accentuate certain architectural features. Figure 5 illustrates the divergent appearances of the basic agronomic categories of Cannabis in typical field configurations.
The main psychoactive constituent of Cannabis was identified as delta-9-tetrahydrocannabinol (THC). In 1986, an isomer of synthetic delta-9-THC in sesame oil was licensed and approved for the treatment of chemotherapy -associated nausea and vomiting under the generic name dronabinol. Clinical trials determined that dronabinol was as effective as or better than other antiemetic agents available at the time. Dronabinol was also studied for its ability to stimulate weight gain in patients with AIDS in the late 1980s. Thus, the indications were expanded to include treatment of anorexia associated with human immunodeficiency virus infection in 1992. Clinical trial results showed no statistically significant weight gain, although patients reported an improvement in appetite.[9,10] Another important cannabinoid found in Cannabis is CBD. This is a nonpsychoactive cannabinoid, which is an analog of THC.
Hi Marilyn, I would recommend a topical lotion or salve to start for instant relief.. Maybe 250 to 300 mg tincture to see how you feel. For me, the salve took the pain in my hands away in under a minute. I didn't notice how much the tincture worked until I forgot to take on vacation. Pain that was pretty much gone but came back, I was tired, grumpy and felt horrible. It works, just need to find right product and dosage for you.
The health consequences of cannabis use in developing countries are largely unknown beacuse of limited and non-systematic research, but there is no reason a priori to expect that biological effects on individuals in these populations would be substantially different to what has been observed in developed countries. However, other consequences might be different given the cultural and social differences between countries.
As in Los Angeles' equity program, the group will offer participants mentorship, job placement, and help with starting businesses in Wisconsin's hemp industry, where close to 220 hemp licenses have already been issued under the current Farm Bill; they also plan to provide on-site housing for participants struggling with homelessness, which often impacts veterans and those recently released from prison.
It's the Wild West out there. Without any federal regulatory body checking labels, consumers have very little way of knowing what they're buying when they purchase CBD oil. Bonn-Miller co-authored a study that found that 26 percent of CBD products on the market contained less CBD than their label claimed. So the amount you need for an effective dose could vary drastically, not just from product to product, but from bottle to bottle of the same product.
Fatty Acids. The quality of an oil or fat is most importantly determined by its fatty acid composition. Hemp is of high nutritional quality because it contains high amounts of unsaturated fatty acids, mostly oleic acid (C18:1, 10%–16%), linoleic acid (C18:2, 50%–60%), alpha-linolenic acid (C18:3, 20%–25%), and gamma-linolenic acid (C18:3, 2%–5%) (Fig. 37). Linoleic acid and alpha-linolenic acid are the only two fatty acids that must be ingested and are considered essential to human health (Callaway 1998). In contrast to shorter-chain and more saturated fatty acids, these essential fatty acids do not serve as energy sources, but as raw materials for cell structure and as precursors for biosynthesis for many of the body’s regulatory biochemicals. The essential fatty acids are available in other oils, particularly fish and flaxseed, but these tend to have unpleasant flavors compared to the mellow, slightly nutty flavor of hempseed oil. While the value of unsaturated fats is generally appreciated, it is much less well known that the North American diet is serious nutritionally unbalanced by an excess of linoleic over alpha-linonenic acid. In hempseed, linoleic and alpha-linolenic occur in a ratio of about 3:1, considered optimal in healthy human adipose tissue, and apparently unique among common plant oils (Deferne and Pate 1996). Gamma-linolenic acid or GLA is another significant component of hemp oil (1%–6%, depending on cultivar). GLA is a widely consumed supplement known to affect vital metabolic roles in humans, ranging from control of inflammation and vascular tone to initiation of contractions during childbirth. GLA has been found to alleviate psoriasis, atopic eczema, and mastalgia, and may also benefit cardiovascular, psychiatric, and immunological disorders. Ageing and pathology (diabetes, hypertension, etc.) may impair GLA metabolism, making supplementation desirable. As much as 15% of the human population may benefit from addition of GLA to their diet. At present, GLA is available in health food shops and pharmacies primarily as soft gelatin capsules of borage or evening primrose oil, but hemp is almost certainly a much more economic source. Although the content of GLA in the seeds is lower, hemp is far easier to cultivate and higher-yielding. It is important to note that hemp is the only current natural food source of GLA, i.e. not requiring the consumption of extracted dietary supplements. There are other fatty acids in small concentrations in hemp seed that have some dietary significance, including stearidonic acid (Callaway et al. 1996) and eicosenoic acid (Mölleken and Theimer 1997). Because of the extremely desirable fatty acid constitution of hemp oil, it is now being marketed as a dietary supplement in capsule form (Fig. 38).
Acute effects may include anxiety and panic, impaired attention, and memory (while intoxicated), an increased risk of psychotic symptoms, and possibly an increased risk of accidents if a person drives a motor vehicle while intoxicated. Short-term cannabis intoxication can hinder the mental processes of organizing and collecting thoughts. This condition is known as temporal disintegration. Psychotic episodes are well-documented and typically resolve within minutes or hours. There have been few reports of symptoms lasting longer.
The public forum sessions provided an overview of the Alternative Crop Research Act, including the legal parameters set within the bill, and the procedures that will guide development of the rules and regulations. Guest speakers included Brent Burchett, the director of the plant division from the Kentucky Department of Agriculture, and Mitch Yergert, retired director of the division of plant industry from the Colorado State Department of Agriculture.
In May of 2018, Mount Vernon planted an industrial cultivar of hemp on the four-acre Pioneer Farm site. Under the 2015 Industrial Hemp Law enacted by the Virginia General Assembly and working with the industrial hemp research program of the University of Virginia, Mount Vernon planted hemp to expand its interpretation of George Washington’s role as an enterprising farmer. As the first historic home of the founding fathers to plant hemp, Mount Vernon will use the plant as an interpretative tool to help better tell the story of Washington’s role as a farmer.
Marijuana or marihuana (herbal cannabis), consists of the dried flowers and subtending leaves and stems of the female Cannabis plant. This is the most widely consumed form, containing 3% to 20% THC, with reports of up-to 33% THC. This is the stock material from which all other preparations are derived. Although herbal cannabis and industrial hemp derive from the same species and contain the psychoactive component (THC), they are distinct strains with unique biochemical compositions and uses. Hemp has lower concentrations of THC and higher concentrations of CBD, which decreases the psychoactive effects
Several of the cannabinoids are reputed to have medicinal potential: THC for glaucoma, spasticity from spinal injury or multiple sclerosis, pain, inflammation, insomnia, and asthma; CBD for some psychological problems. The Netherlands firm HortaPharm developed strains of Cannabis rich in particular cannabinoids. The British firm G.W. Pharmaceuticals acquired proprietary access to these for medicinal purposes, and is developing medicinal marijuana. In the US, NIH (National Institute of Health) has a program of research into medicinal marijuana, and has supplied a handful of individuals for years with maintenance samples for medical usage. The American Drug Enforcement Administration is hostile to the medicinal use of Cannabis, and for decades research on medicinal properties of Cannabis in the US has been in an extremely inhospitable climate, except for projects and researchers concerned with curbing drug abuse. Synthetic preparations of THC—dronabinol (Marinol®) and nabilone (Cesamet®)—are permitted in some cases, but are expensive and widely considered to be less effective than simply smoking preparations of marijuana. Relatively little material needs to be cultivated for medicinal purposes (Small 1971), although security considerations considerably inflate costs. The potential as a “new crop” for medicinal cannabinoid uses is therefore limited. However, the added-value potential in the form of proprietary drug derivatives and drug-delivery systems is huge. The medicinal efficacy of Cannabis is extremely controversial, and regrettably is often confounded with the issue of balancing harm and liberty concerning the proscriptions against recreational use of marijuana. This paper is principally concerned with the industrial uses of Cannabis. In this context, the chief significance of medicinal Cannabis is that, like the issue of recreational use, it has made it very difficult to rationally consider the development of industrial hemp in North America for purposes that everyone should agree are not harmful.
Both in Canada and the US, the most critical problem to be addressed for commercial exploitation of C. sativa is the possible unauthorized drug use of the plant. Indeed, the reason hemp cultivation was made illegal in North America was concern that the hemp crop was a drug menace. The drug potential is, for practical purposes, measured by the presence of THC. THC is the world’s most popular illicit chemical, and indeed the fourth most popular recreational drug, after caffeine, alcohol, and nicotine. “Industrial hemp” is a phrase that has become common to designate hemp used for commercial non-intoxicant purposes. Small and Cronquist (1976) split C. sativa into two subspecies: C. sativa subsp. sativa, with less than 0.3% (dry weight) of THC in the upper (reproductive) part of the plant, and C. sativa subsp. indica (Lam.) E. Small & Cronq. with more than 0.3% THC. This classification has since been adopted in the European Community, Canada, and parts of Australia as a dividing line between cultivars that can be legally cultivated under license and forms that are considered to have too high a drug potential. For a period, 0.3% was also the allowable THC content limit for cultivation of hemp in the Soviet Union. In the US, Drug Enforcement Agency guidelines issued Dec. 7, 1999 expressly allowed products with a THC content of less than 0.3% to enter the US without a license; but subsequently permissible levels have been a source of continuing contention. Marijuana in the illicit market typically has a THC content of 5% to 10% (levels as high as 25% have been reported), and as a point of interest, a current Canadian government experimental medicinal marijuana production contract calls for the production of 6% marijuana. As noted above, a level of about 1% THC is considered the threshold for marijuana to have intoxicating potential, so the 0.3% level is conservative, and some countries (e.g. parts of Australia, Switzerland) have permitted the cultivation of cultivars with higher levels. It should be appreciated that there is considerable variation in THC content in different parts of the plant. THC content increases in the following order: achenes (excluding bracts), roots, large stems, smaller stems, older and larger leaves, younger and smaller leaves, flowers, perigonal bracts covering both the female flowers and fruits. It is well known in the illicit trade how to screen off the more potent fractions of the plant in order to increase THC levels in resultant drug products. Nevertheless, a level of 0.3% THC in the flowering parts of the plant is reflective of material that is too low in intoxicant potential to actually be used practically for illicit production of marijuana or other types of cannabis drugs. Below, the problem of permissible levels of THC in food products made from hempseed is discussed.
When oral Cannabis is ingested, there is a low (6%–20%) and variable oral bioavailability.[1,2] Peak plasma concentrations of delta-9-tetrahydrocannabinol (THC) occur after 1 to 6 hours and remain elevated with a terminal half-life of 20 to 30 hours. Taken by mouth, delta-9-THC is initially metabolized in the liver to 11-OH-THC, a potent psychoactive metabolite. Inhaled cannabinoids are rapidly absorbed into the bloodstream with a peak concentration in 2 to 10 minutes, declining rapidly for a period of 30 minutes and with less generation of the psychoactive 11-OH metabolite.
An alternative to the gateway hypothesis is the common liability to addiction (CLA) theory. It states that some individuals are, for various reasons, willing to try multiple recreational substances. The "gateway" drugs are merely those that are (usually) available at an earlier age than the harder drugs. Researchers have noted in an extensive review that it is dangerous to present the sequence of events described in gateway "theory" in causative terms as this hinders both research and intervention.
Despite its designation as having no medicinal use, Cannabis was distributed by the U.S. government to patients on a case-by-case basis under the Compassionate Use Investigational New Drug program established in 1978. Distribution of Cannabis through this program was closed to new patients in 1992.[1-4] Although federal law prohibits the use of Cannabis, Figure 1 below shows the states and territories that have legalized Cannabis use for medical purposes. Additional states have legalized only one ingredient in Cannabis, such as cannabidiol (CBD), and are not included in the map. Some medical marijuana laws are broader than others, and there is state-to-state variation in the types of medical conditions for which treatment is allowed.
The use of Cannabis for seed oil (Fig. 36) began at least 3 millennia ago. Hempseed oil is a drying oil, formerly used in paints and varnishes and in the manufacture of soap. Present cultivation of oilseed hemp is not competitive with linseed for production of oil for manufacturing, or to sunflower and canola for edible vegetable oil. However, as noted below, there are remarkable dietary advantages to hempseed oil, which accordingly has good potential for penetrating the salad oil market, and for use in a very wide variety of food products. There is also good potential for hemp oil in cosmetics and skin-care products.
Plus CBD Oil™ products come in a variety of flavors and concentrations to suit your preferences. If you are considering CBD oil for your health, as with any supplement, we encourage you to speak with your physician and dive into the research to learn more about this promising phytonutrient. We at Plus CBD Oil™ are proud of our innovative selection of products.
The use of Cannabis as a mind-altering drug has been documented by archaeological finds in prehistoric societies in Eurasia and Africa. The oldest written record of cannabis usage is the Greek historian Herodotus's reference to the central Eurasian Scythians taking cannabis steam baths. His (c. 440 BCE) Histories records, "The Scythians, as I said, take some of this hemp-seed [presumably, flowers], and, creeping under the felt coverings, throw it upon the red-hot stones; immediately it smokes, and gives out such a vapour as no Grecian vapour-bath can exceed; the Scyths, delighted, shout for joy." Classical Greeks and Romans were using cannabis, while in the Middle East, use spread throughout the Islamic empire to North Africa. In 1545, cannabis spread to the western hemisphere where Spaniards imported it to Chile for its use as fiber. In North America, cannabis, in the form of hemp, was grown for use in rope, clothing and paper.
About 9% of those who experiment with marijuana eventually become dependent according to DSM-IV (1994) criteria. A 2013 review estimates daily use is associated with a 10-20% rate of dependence. The highest risk of cannabis dependence is found in those with a history of poor academic achievement, deviant behavior in childhood and adolescence, rebelliousness, poor parental relationships, or a parental history of drug and alcohol problems. Of daily users, about 50% experience withdrawal upon cessation of use (i.e. are dependent), characterized by sleep problems, irritability, dysphoria, and craving. Cannabis withdrawal is less severe than withdrawal from alcohol.
In Canada, the methodology used for analyses and sample collection for THC analysis of hemp plantings is standardized (at the Health Canada/Therapeutics Program/Hemp web site at www.hc-sc.gc.ca/hpb-dgps/therapeut/htmleng/hemp.html, see “Industrial Hemp Technical Manual” for procedures on sampling plant materials and chemical procedures for determining THC levels). The regulations require that one of the dozen independent laboratories licensed for the purpose conduct the analyses and report the results to Health Canada. Sample collection is also normally carried out by an independent authorized firm. The Canadian system of monitoring THC content has rigidly limited hemp cultivation to cultivars that consistently develop THC levels below 0.3%.